Vyvanse® (lisdexamfetamine dimesilate) for treatment of adults with ADHD
Vyvanse® (lisdexamfetamine dimesilate) for treatment of adults with ADHD: PBS listed from 1 February 20211,2
ATAGI highlights progress amid resurgent diseases
ATAGI flagged worrying vaccine coverage declines and renewed disease threats, with pharmacists tipped to boost community protection.
Vaccination key to preventing a devastating flu season
An expert weighs in on the factors driving influenza cases in 2023 and how pharmacists can encourage vaccination in all patients.
A wrap-around approach to managing endometriosis
With a new medicine available for endometriosis, here's how pharmacists can screen for the ‘missed disease’ and discuss appropriate options.
Aus CVD risk: the Australian cardiovascular disease risk calculator
The 2023 Aus CVD Risk calculator and guideline provide updated evidence-based recommendations for identifying, assessing, communicating and managing CVD risk in a primary prevention setting.
A pharmacist’s role in drug discovery
Pharmacists have a critical role to play in the optimisation of drug discovery research due to the diversity of their drug knowledge.
